COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01693640
Recruitment Status : Completed
First Posted : September 26, 2012
Last Update Posted : January 28, 2019
Bristol-Myers Squibb
Information provided by (Responsible Party):
NYU Langone Health

Brief Summary:
Hypothesis: Abatacept injections will decrease the number of oral ulcers seen in Behcet's patients

Condition or disease Intervention/treatment Phase
Female Patients With Behcet's Syndrome Drug: Abatacept Early Phase 1

Detailed Description:
This will be an open label study, where 20 Behcet's patients with resistant oral ulcers and 10 with resistant genital ulcers will be enrolled (screen 40). After enrollment all patients will be followed for a month to document the number of oral and genital ulcers on their current regimen. Then all patients will receive abatacept for 6 months (evaluated at weeks 0, 2, 4, 8, 12, 16 and 24). Then the treatment will be stopped and they will be observed for the next 2 months, for a total of 9 month trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Mucocutaneous Manifestations of Behcet's Syndrome
Actual Study Start Date : June 2012
Actual Primary Completion Date : December 28, 2018
Actual Study Completion Date : December 28, 2018

Arm Intervention/treatment
Experimental: abatacept Drug: Abatacept
Weekly injections with Abatacept 125 mg over 6 months
Other Name: Orencia

Primary Outcome Measures :
  1. ulcers [ Time Frame: 6 month treatment period ]
    The primary endpoint is number of oral and genital ulcers (AUC) during the treatment period

Secondary Outcome Measures :
  1. Genital ulcers [ Time Frame: 6 month treatment ]
    Number of genital ulcers

  2. Treatment failures [ Time Frame: 6 months ]
    Number of patients who fail to complete 6 months (treatment failures)

  3. Oral ulcer pain [ Time Frame: 6 months ]
    Oral ulcer pain-Visual Analog Scale (VAS)

  4. Side Effects [ Time Frame: 6 months ]
    Monitoring of side effects

  5. MDHAQ [ Time Frame: 6 months ]
    Multidimensional health assessment questionnaire (MDHAQ)

  6. BSAS [ Time Frame: 6 months ]
    Behcet's syndrome activity score (BSAS)

  7. BDCAF [ Time Frame: 6 months ]
    Behcet's disease current activity form (BDCAF) scores

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Before any study procedures are performed, subjects will have the details of the study described to them, and they will be given a written informed consent document to read. Then, if subjects consent to participate in the study, they will indicate that consent by signing and dating the informed consent document in the presence of study personnel.
  2. Female patients with a diagnosis of Behcet's syndrome
  3. Women, greater than 18 years of age
  4. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 10 weeks after the last dose of study drug to minimize the risk of pregnancy.
  5. Patients must have oral ulcers or genital ulcers that have been resistant to colchicine or topical measures for at least a month.

Exclusion Criteria:

  1. WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study drug.
  2. Women who are pregnant or breastfeeding.
  3. Women with a positive pregnancy test on enrollment or before administration of abatacept.

    Target Disease Exceptions [Include as applicable]

    • Any patients with systemic manifestations of Behcet's syndrome (Patients with eye, CNS, vascular involvement, gastrointestinal disease)
    • Patients who are already on other immunosuppressive medications (azathioprine, TNF inhibitors, other biologic agents, methotrexate, mycophenolate mofetil, cyclosporine, cyclophosphamide)
  4. Subjects who are impaired, incapacitated, or incapable of completing study-related assessments.
  5. Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to Behcet's syndrome and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
  6. Female subjects who have had a breast cancer screening that is suspicious for malignancy and in whom the possibility of malignancy cannot be reasonably excluded by additional clinical, laboratory, or other diagnostic evaluations.
  7. Subjects with a history of cancer in the last 5 years, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ.
  8. Subjects who currently abuse drugs or alcohol.
  9. Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of human immunodeficiency virus (HIV) detected during screening.
  10. Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed.
  11. Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication.
  12. Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis, or bronchiectasis).
  13. Subjects at risk for tuberculosis (TB).
  14. Subjects must not be positive for hepatitis B surface antigen.
  15. Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay.
  16. Subjects with any of the following laboratory values
  17. Hemoglobin < 8.5 g/dL
  18. WBC < 3000/mm3 (< 3 x 109/L)
  19. Platelets < 100,000/mm3 (< 3 x 109/L)
  20. Serum creatinine > 2 times the ULN
  21. Serum ALT or AST > 2 times the ULN
  22. Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
  23. Subjects who have at any time received treatment with any investigational drug within 28 days (or less than 5 terminal half-lives of elimination) of the Day 1 dose.
  24. Any concomitant biologic DMARD.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01693640

Layout table for location information
United States, New York
NYU Center for Musculoskeletal Care
New York, New York, United States, 10016
Sponsors and Collaborators
NYU Langone Health
Bristol-Myers Squibb

Additional Information:
Layout table for additonal information
Responsible Party: NYU Langone Health Identifier: NCT01693640    
Other Study ID Numbers: 10-02611
First Posted: September 26, 2012    Key Record Dates
Last Update Posted: January 28, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NYU Langone Health:
Additional relevant MeSH terms:
Layout table for MeSH terms
Behcet Syndrome
Pathologic Processes
Mouth Diseases
Stomatognathic Diseases
Uveitis, Anterior
Uveal Diseases
Eye Diseases
Vascular Diseases
Cardiovascular Diseases
Hereditary Autoinflammatory Diseases
Genetic Diseases, Inborn
Skin Diseases, Genetic
Skin Diseases
Skin Diseases, Vascular
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents